[go: up one dir, main page]

WO2006128176A3 - Molecules composites avec fonction g-csf - Google Patents

Molecules composites avec fonction g-csf Download PDF

Info

Publication number
WO2006128176A3
WO2006128176A3 PCT/US2006/020917 US2006020917W WO2006128176A3 WO 2006128176 A3 WO2006128176 A3 WO 2006128176A3 US 2006020917 W US2006020917 W US 2006020917W WO 2006128176 A3 WO2006128176 A3 WO 2006128176A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
csf
composite molecules
csf function
composite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/020917
Other languages
English (en)
Other versions
WO2006128176A2 (fr
Inventor
Darryl L Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nora LLC
Original Assignee
Nora LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nora LLC filed Critical Nora LLC
Publication of WO2006128176A2 publication Critical patent/WO2006128176A2/fr
Publication of WO2006128176A3 publication Critical patent/WO2006128176A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des molécules de fusion composites à facteur de stimulation des colonies de granulocytes ('G-CSF') ainsi que des compostions contenant de telles molécules, lesquelles conservent les fonctions G-CSF en rapport, par exemple, l'adaptation du système de reproduction. Sont également décrites des méthodes de détermination et de fabrication d'analogues, des dérivés, de molécules hybrides et de modifications.
PCT/US2006/020917 2005-05-26 2006-05-26 Molecules composites avec fonction g-csf Ceased WO2006128176A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68472405P 2005-05-26 2005-05-26
US60/684,724 2005-05-26

Publications (2)

Publication Number Publication Date
WO2006128176A2 WO2006128176A2 (fr) 2006-11-30
WO2006128176A3 true WO2006128176A3 (fr) 2007-01-11

Family

ID=37452997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/020917 Ceased WO2006128176A2 (fr) 2005-05-26 2006-05-26 Molecules composites avec fonction g-csf

Country Status (1)

Country Link
WO (1) WO2006128176A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
DK2441465T3 (da) 2003-10-24 2014-04-14 Nora Therapeutics Inc Præparater og fremgangsmåder til en sund graviditet
WO2010126528A1 (fr) * 2009-05-01 2010-11-04 Nora Therapeutics, Inc. Compositions et procédés pour réduire la probabilité d'un échec d'implantation ou d'une fausse couche chez des receveuses d'une insémination artificielle
CA3159912A1 (fr) 2019-12-17 2021-06-24 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nouvelles imitations de g-csf et leurs applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003737A1 (fr) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Proteines de fusion d'immunoglobine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003737A1 (fr) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Proteines de fusion d'immunoglobine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABE ET AL.: "A Patient with Cyclic Neutropenia Complicated by Severe Persistent Neutropenia Successfully Delivered a Healthy Baby", INTERNAL MEDICINE, vol. 39, no. 8, August 2000 (2000-08-01), pages 663 - 666, XP008075549 *
COX ET AL.: "Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein", EXPERIMENTAL HEMATOLOGY, vol. 32, 2004, pages 441 - 449, XP003006681 *

Also Published As

Publication number Publication date
WO2006128176A2 (fr) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2007076032A3 (fr) Compositions et procédés de production d'une composition
WO2006028936A3 (fr) Molecules heteromultimeriques
WO2008027812A3 (fr) Dérivés d'imidazopyridine et d'imidazopyrimidine
WO2007009109A3 (fr) Composes antiviraux
WO2004035170A3 (fr) Composition permettant de separer des molecules
WO2006020276A3 (fr) Composés antiviraux
WO2006120208A8 (fr) Procedes de preparation de derives de benzylbenzene a substitution glucopyranosyl et intermediaires obtenus selon ces procedes
WO2006072393A3 (fr) Sulfonylpyrrolidines, procede pour les produire et leur utilisation comme medicaments
WO2007062399A3 (fr) Compose cytotoxique speficique du ras oncogene et ses procedes d’utilisation
MX2008010481A (es) Compuestos que tienen afinado para el receptor f-ht6.
WO2008048589A3 (fr) Composés et procédés pour le traitement du virus de l'hépatite c
IL169370A0 (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
WO2009023844A3 (fr) Composés substitués en position 3' ayant une affinité vis-à-vis du récepteur 5-ht<sb>6</sb>
WO2004093800A3 (fr) Derives de thyronamine et analogues et des methodes d'utilisation de ces composes
WO2003006070A3 (fr) Conjugues de chelateurs ameliores
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
WO2006091457A3 (fr) Liquides ioniques derives d'anions de peracides
ZA200604410B (en) Imidazole derivatives, processes for preparing them and their uses
WO2006119400A3 (fr) 4,5-dihydro-1,2,4-triazin-6-ones, 1,2,4-trianzin-6-ones substituees et leur utilisation comme fongicides
WO2008147812A3 (fr) Composés 4' substitués ayant une affinité de récepteur 5-ht6
WO2006114520A3 (fr) Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
WO2007083060A3 (fr) Derives de chalcone a activite antimitotique
WO2004106322A3 (fr) Polymorphes d'aripiprazole
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
WO2007065595A3 (fr) Derives de la xanthine, procedes de preparation et utilisations de ceux-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06771595

Country of ref document: EP

Kind code of ref document: A2